Yavuz Yüksel1, Cüneyt Aytekin2 Radiofrequency Ablation Treatment Results in Primary and Metastatic Liver Cancers Ş.E.E.A.H. Medical Bulletin 2017; 51 (3): 225-33
Abstract :
In the treatment of liver tumors, surgical resection is the curative and preferred treatment method. However, in these patients, the number and distribution of tumoral lesions, markedly impaired liver function and other accompanying systemic problems decrease the chance of surgical resection in these patients (1). Treatment options have been developed to assist local tumor control for such patients who are not amenable to surgery. Methods such as transarterial chemoembolization (TAKE), percutaneous ethanol injection (PEE), cryotherapy, interstitial laser therapy, microwave coagulation and radiofrequency ablation (RFA) are the local methods of treatment used today (2,3). Radiofrequency ablation, especially compared to other local ablation methods; Due to its advantages such as cheaper and easier to apply, low risk of complications, and more thermal damage in a single session, it is a more preferred method for local control of liver tumors in recent years, the size and severity of ablation can be determined in advance and controlled during the procedure. is the most obvious advantage of radiofrequency ablation over other ablation methods such as PEE (4,5). At the same time, RFA treatment is considered to be the most effective among the methods that provide local tumor control for tumors that cannot be surgically resected (6). In this study; We aimed to retrospectively evaluate the local therapeutic effectiveness of RFA therapy in patients with primary or metastatic liver cancers. The clinical and radiological follow-up of the patients were evaluated after RFA treatment, local tumor growth and new lesion formation. In addition, factors that may affect survival, local tumor growth and new lesion formation were evaluated.
The result:
Our primary and metastatic liver cancer patients with RFA therapy extend and support the results of other studies conducted in the literature on the same subject in the literature. At the same time, our results are similarly successful compared to other studies on this subject. Besides the technological developments in RFA treatment, the increase in experience in the application of this method has a positive effect on the results. However, considering the advantages such as not requiring general anesthesia, being minimally invasive, being combined with other treatment methods, low cost, and short hospital stay, RFA therapy alone maintains its place in liver cancer treatment in combination with other local treatment methods. .
References: 1. Dodd GD 3rd, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000; 20: 9-27. [CrossRef] 2. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119: 647-51. [CrossRef] 3. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210: 127-38. [CrossRef] 4. McWilliams JP, Yamamoto S, Raman SS, Loh CT, Lee EW, Liu DM, et al. Percutaneous ablation of hepatocellular carcinoma: current status J Vasc Interv Radiol 2010; 21: 204-13. [CrossRef] 5. Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices J Vasc Interv Radiol 2010; 21: 179-86. [CrossRef] 6. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003; 197: 759-64. [CrossRef] 7. Lin SM. Recent advances in radiofrequency ablation in the treatment of hepatocellular carcinoma and metastatic liver cancers. Chang Gung Med J 2009; 32: 22-32. 8. Chen MH, Yang W, Yan K, Gao W, Dai Y, Wang YB, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005; 11: 6395-401. [CrossRef] 9. Gillams AR. The use of radiofrequency in cancer. Br J Cancer 2005; 92: 1825-9. [CrossRef] 10. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010; 10: 78. [CrossRef] 11. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-40. [CrossRef] 12. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. Gastroenterology 2004; 127: 1714-23. [CrossRef] 13. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomized controlled trial comparing percutaneous radio-frequency thermal ablation, percutaneous ethanol injection and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-6. [CrossRef] 14. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-30. [CrossRef] 15. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percuataneous image-guided radiofrequency ablation. Radiology 2005; 234: 961-7. [CrossRef] 16. Cammà C, Di Marco V, Orlando A, Sandonato L, Casaril A, Parisi P, et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005; 42: 535-40. [CrossRef] 17. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999; 230: 1-8. [CrossRef] 18. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221: 159-66. [CrossRef] 19. Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 2004; 14: 2261-7. [CrossRef] 20th Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175: 1619-25. [CrossRef] Şişli Etfal Hospital Medical Bulletin, Volume: 51, Number: 3, 2017 / The Medical Bulletin of Sisli Etfal Hospital, Volume: 51, Number 3, 2017 233 Y. Yüksel, C. Aytekin 21. Gillams AR , Lees WR. Survival after percutaneous, imageguided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 2000; 43: 656-61. [CrossRef] 22. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10: 1059-69. [CrossRef] 23. Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003; 97: 1253-62. [CrossRef]24. Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 2003; 38: 977-81. [CrossRef] 25. Zytoon AA, Ishii H, Murakami K, El-Kholy MR, Furuse J, El-Dorry A, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. JPN J Clin Oncol 2007; 37: 658-72. [CrossRef] 26. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 2008; 12: 183-91.
